Fresenius Medical Care

Invizius Announces Appointment of World-Renowned Nephrologist Professor Bernard Canaud to its Clinical Advisory Board

Retrieved on: 
Tuesday, October 24, 2023
ISN, Legion, SFD, Health care, Hemodialysis, American Society of Nephrology, Children's Organ Transplant Association, Quality of life, Society, International Society of Nephrology, Dialysis, Growth, Legion of Honour, MHRA, ASN, Risk, Kidney disease, EDTA, Fresenius Medical Care, International Society, Pennsylvania Convention Center, Patient, Pharmaceutical industry, Nursing, Nephrology

GLASGOW, Scotland, Oct. 24, 2023 /PRNewswire/ -- Invizius Limited ("Invizius"), a biotechnology company developing breakthrough treatments for patients on dialysis, is pleased to announce the appointment of Professor Bernard Canaud to its Clinical Advisory Board.

Key Points: 
  • GLASGOW, Scotland, Oct. 24, 2023 /PRNewswire/ -- Invizius Limited ("Invizius"), a biotechnology company developing breakthrough treatments for patients on dialysis, is pleased to announce the appointment of Professor Bernard Canaud to its Clinical Advisory Board.
  • Professor Canaud is a leading authority on kidney disease and dialysis.
  • Richard Boyd, Chief Executive Officer of Invizius, said: "We are delighted and honored to have Professor Canaud join Invizius at an important time of growth and development for the company.
  • Professor Bernard Canaud, commented: "Invizius' unique product H-Guard has the potential to reduce the therapeutic burden and save patients' lives by addressing the inappropriate activation of the complement system.

Invizius Announces Appointment of World-Renowned Nephrologist Professor Bernard Canaud to its Clinical Advisory Board

Retrieved on: 
Tuesday, October 24, 2023
ISN, Legion, SFD, Health care, Hemodialysis, American Society of Nephrology, Children's Organ Transplant Association, Quality of life, Society, International Society of Nephrology, Dialysis, Growth, Legion of Honour, MHRA, ASN, Risk, Kidney disease, EDTA, Fresenius Medical Care, International Society, Pennsylvania Convention Center, Patient, Pharmaceutical industry, Nursing, Nephrology

GLASGOW, Scotland, Oct. 24, 2023 /PRNewswire/ -- Invizius Limited ("Invizius"), a biotechnology company developing breakthrough treatments for patients on dialysis, is pleased to announce the appointment of Professor Bernard Canaud to its Clinical Advisory Board.

Key Points: 
  • GLASGOW, Scotland, Oct. 24, 2023 /PRNewswire/ -- Invizius Limited ("Invizius"), a biotechnology company developing breakthrough treatments for patients on dialysis, is pleased to announce the appointment of Professor Bernard Canaud to its Clinical Advisory Board.
  • Professor Canaud is a leading authority on kidney disease and dialysis.
  • Richard Boyd, Chief Executive Officer of Invizius, said: "We are delighted and honored to have Professor Canaud join Invizius at an important time of growth and development for the company.
  • Professor Bernard Canaud, commented: "Invizius' unique product H-Guard has the potential to reduce the therapeutic burden and save patients' lives by addressing the inappropriate activation of the complement system.

Capital Square Delivers 149.59% Total Return* to Investors in Medical Building DST

Retrieved on: 
Wednesday, October 18, 2023
Frankfurt Stock Exchange, Sale, NYSE, Internal Revenue Code, Medicine, Internal Revenue Code section 1031, Capital Square, WINCHESTER, Fresenius Medical Care, DST, Fresenius, FMS, New York Stock Exchange, DAX, Commercial property

*

Key Points: 
  • *
    "Capital Square has acquired a large number of medical buildings in the southeast for the Section 1031 DST exchange program," said Louis Rogers, founder and co-chief executive officer of Capital Square.
  • "Medical assets are well known for providing stable income, preservation of capital and capital appreciation.
  • Since 2018, Capital Square has taken 24 DST offerings full cycle that have resulted in an average 173.51% total return and an average 14.53% internal rate of return.
  • Located at 38 W. Jubal Early Dr., the single-story Winchester medical building was acquired by Capital Square in July 2016.

BJ’s Wholesale Club Names Anjana Harve Executive Vice President, Chief Information Officer

Retrieved on: 
Monday, September 11, 2023
Supermarket, Retail, Discount, Variety, Department Stores, Fresenius Medical Care, University, BJ, Information technology, Bangalore University, Loblaw Companies, University of Pennsylvania, Multimedia, Privacy, Wharton School of the University of Pennsylvania, Novartis, BJ's Wholesale Club, Hill-Rom, Engineering, Harve, Widener University Commonwealth Law School, CIO, NYSE, Management

BJ's Wholesale Club (NYSE: BJ) (“BJ’s”), a leading operator of membership warehouse clubs, today announced that Anjana Harve has been named Executive Vice President, Chief Information Officer, effective immediately.

Key Points: 
  • BJ's Wholesale Club (NYSE: BJ) (“BJ’s”), a leading operator of membership warehouse clubs, today announced that Anjana Harve has been named Executive Vice President, Chief Information Officer, effective immediately.
  • Harve will report to Bob Eddy, Chairman and Chief Executive Officer, and serve as a member of BJ’s executive leadership team.
  • “She brings more than 25 years of experience driving innovative technology transformations and leading and inspiring high-performing teams.
  • She also held various CIO and technology leadership roles at Hill-Rom, Novartis and Shire, along with other senior management positions during her career.

CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil

Retrieved on: 
Thursday, August 31, 2023
Blood pressure, Fresenius Medical Care, Critical care, Surgeon, Shock, ANVISA, Oxygen, Cardiac surgery, COVID-19, Cytokine adsorbing column, COVID, Inflammation, Septic shock, Marketing, Professional corporation, Sepsis, Patient, Cytosorbents Corporation, FMC, Nursing care plan, ICU, Brazilian Health Regulatory Agency, Death, Pharmaceutical industry, Hospital

PRINCETON, N.J., Aug. 31, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care therapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that CytoSorb® was granted an expanded medical device registration by the Brazilian Health Regulatory Agency (ANVISA) to treat shock.

Key Points: 
  • PRINCETON, N.J., Aug. 31, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care therapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that CytoSorb® was granted an expanded medical device registration by the Brazilian Health Regulatory Agency (ANVISA) to treat shock.
  • After receiving its first ANVISA registration in September 2020 to treat cytokine storm in cardiac surgery and critical illnesses such as COVID-19 in the midst of the COVID pandemic, CytoSorb has now received an expanded ANVISA registration to also include the treatment of shock – a common and frequently fatal complication of critical illness and cardiac surgery.
  • Mr. Alexandre Franco, Marketing Director of FMC Brazil, stated, “Fresenius Brazil is very proud of the registration approval of CytoSorb by ANVISA, which will help anchor our Critical Care portfolio.
  • We are pleased to commercialize CytoSorb in Brazil under this expanded registration through our partners FMC and Contatti Medical, both well-established and connected experts in their respective clinical fields.

Fresenius Medical Care Announces FDA Clearance of Versi®HD with GuideMe Software

Retrieved on: 
Wednesday, August 23, 2023
Fresenius Medical Care, Senior, HHD, Chronic kidney disease, Atmosphere, Frankfurt Stock Exchange, Connected health, COVID-19, All rights reserved, Dialysis, Patient, NxStage, Nursing, Nocturnality, Kidney, Water, FME, Bleeding, FMS, Health, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Environment, Food, Medical device

"We expect VersiHD with GuideMe Software to further simplify home hemodialysis for patients during training and at home," said Dr. Brigitte Schiller, Senior Vice President, Medical Officer, Home Therapies at Fresenius Medical Care.

Key Points: 
  • "We expect VersiHD with GuideMe Software to further simplify home hemodialysis for patients during training and at home," said Dr. Brigitte Schiller, Senior Vice President, Medical Officer, Home Therapies at Fresenius Medical Care.
  • VersiHD with GuideMe Software will support Fresenius Medical Care's mission of advancing access to home therapies to more patients."
  • Fresenius Medical Care, NxStage, the triangle logo, VersiHD, PureFlow and Nx2me are trademarks of Fresenius Medical Care Holdings, Inc. or its affiliated companies.
  • Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius Medical Care Partners with Sarah Bush Lincoln to Provide Life-Sustaining Care to Rural Patients

Retrieved on: 
Wednesday, August 9, 2023
Insurance, Fresenius Medical Care, Partnership, Travel, CDN, Senior, Chronic kidney disease, Atmosphere, Renal Physicians Association, Frankfurt Stock Exchange, Decontamination, All rights reserved, MBA, Rehabilitation, BSN, Dialysis, Hospital, Patient, NxStage, Nursing, Kidney, Sarah Bush Lincoln, RN, FMS, Bleeding, Environment, FME, Medical device

WALTHAM, Mass., Aug. 9, 2023 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases has launched an on-site dialysis program with Sarah Bush Lincoln, a regional health system in Mattoon, IL. This program now provides dialysis services with the NxStage VersiHD home hemodialysis system to patients in the local community who previously had to travel 100 miles to receive care. By keeping patients at the local hospital, the doctors and nurses have visibility to all other diagnostics and treatments.

Key Points: 
  • When Sarah Bush Lincoln first implemented the NxStage VersiHD in partnership with Fresenius Medical Care in September of 2022, they quickly discovered their dialysis volumes grew significantly higher than anticipated, resulting in several hundred treatments thus far.
  • Fresenius Medical Care, the triangle logo, NxStage, and Versi are trademarks of Fresenius Medical Care Holdings, Inc. or its affiliated companies.
  • Through its network of 4,050 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approximately 344,000 patients around the globe.
  • Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

DocGo Announces Record Second Quarter 2023 Results

Retrieved on: 
Monday, August 7, 2023
Health, Technology, Telemedicine, Virtual Medicine, Practice Management, Telecommunications, General Health, Networks, Kidney disease, Uncertainty, Fresenius Medical Care, Partnership, Chronic kidney disease, Diabetes, Conference call, COVID-19, MHealth, GAAP, Transport, COVID, CDC, New Yorker, EBITDA, Patient, Nephrology, Housing, Region of Peel Accessible Transportation Services, Colorado EKG Repository, Webcast, Growth, RPM, Adjustment, Social work, Medtech, Conference, Video game, Medical device, Pharmaceutical industry

Total revenue for the second quarter of 2023 was $125.5 million, up from $113.0 million in the first quarter of 2023 and $109.5 million in the second quarter of 2022.

Key Points: 
  • Total revenue for the second quarter of 2023 was $125.5 million, up from $113.0 million in the first quarter of 2023 and $109.5 million in the second quarter of 2022.
  • Gross margin for the second quarter of 2023 was 33.4%, compared to 28.1% in the first quarter of 2023 and 35.9% in the second quarter of 2022.
  • Adjusted EBITDA2 was $9.1 million for the second quarter of 2023 compared to $5.6 million in the first quarter of 2023 and $12.3 million for the second quarter of 2022.
  • Mobile Health revenue for the second quarter of 2023 was $80.1 million, compared to $72.9 million in the first quarter of 2023 and $87.3 million for the second quarter of 2022.

Brett Cohen Named CEO of Recovery Centers of America

Retrieved on: 
Monday, July 31, 2023
Yale University, RCA, Fresenius Medical Care, Kindred Healthcare, Suds, High Watch Recovery Center, Disability, Wharton School of the University of Pennsylvania, Long-term care, MBA, Alumni, Philosophy, Patient, Humble Oil, Growth, UnitedHealth Group, Management, Pharmaceutical industry

King of Prussia, PA, July 31, 2023 (GLOBE NEWSWIRE) -- Recovery Centers of America (RCA), the premier healthcare network for substance use disorder treatment, today named Brett I. Cohen as Chief Executive Officer (CEO).

Key Points: 
  • King of Prussia, PA, July 31, 2023 (GLOBE NEWSWIRE) -- Recovery Centers of America (RCA), the premier healthcare network for substance use disorder treatment, today named Brett I. Cohen as Chief Executive Officer (CEO).
  • Cohen succeeds J. Brian O’Neill as CEO of the company.
  • Cohen was most recently Chief Operating Officer at Sevita, a leading home and community-based healthcare provider with over 40,000 employees.
  • If you or your loved one are struggling with drug or alcohol addiction and need help, the staff at Recovery Centers of America is available 24/7.

Fresenius Medical Care simplifies corporate structure by converting into a German stock corporation

Retrieved on: 
Friday, July 14, 2023
Fresenius Medical Care, West Coast of Vancouver Island Aquatic Management Board, Partnership, Frankfurt Stock Exchange, COVID-19, Supervisory board, AG, Mass meeting, EGM, Limited partnership, Cyprus Securities and Exchange Commission, Dialysis, Professor, Patient, Kidney, Aktiengesellschaft, Kommanditgesellschaft, FMS, Remuneration, FME, Chair, Nursing, Pharmaceutical industry

Michael Sen, Chair of the Supervisory Board of Fresenius Medical Care AG, said: "Our shareholders' vote today clearly is a sign of confidence showing that we are on the right track with Fresenius and with Fresenius Medical Care.

Key Points: 
  • Michael Sen, Chair of the Supervisory Board of Fresenius Medical Care AG, said: "Our shareholders' vote today clearly is a sign of confidence showing that we are on the right track with Fresenius and with Fresenius Medical Care.
  • Helen Giza, CEO of Fresenius Medical Care AG, said: "Today's decision of our shareholders to convert Fresenius Medical Care into a German stock corporation opens a new chapter in the development of the Company.
  • Following the conversion into a German stock corporation, Fresenius Medical Care will have a standard German two-tier Board system that is familiar to shareholders and in line with widely recognized corporate governance practices.
  • Today, the new Supervisory Board of Fresenius Medical Care AG also formally appointed the Management Board of the future Fresenius Medical Care AG, which consists of the members of the existing Management Board of Fresenius Medical Care Management AG.